Helsinn announces license agreement with Specialised Therapeutics for palonosetron in Australia / Leading anti-nausea drug available to Australian and New Zealand cancer patients
Lugoano, Switzerland/Melbourne, Australia (ots) - Australians can now access a new drug to prevent acute (and delayed phase) nausea and vomiting which may occur in cancer patients undergoing chemotherapy1. This follows an agreement between the Swiss pharmaceutical group Helsinn and Specialised Therapeutics ...